Astellas bets on Immunomic’s allergy vaccine in a $75M deal

Damian Garde Astellas Pharma is teaming up with biotech Immunomic Therapeutics on a vaccine that could relieve a common allergy that affects millions in its native Japan. FierceBiotech ...

Branded drug prices leapt almost 15% last year, led by pain pills, COPD and heart meds

Carly Helfand It's no secret that branded drugmakers often rely on price hikes to keep U.S. sales growth coming, especially on older meds whose patents are close to the ends of ...

Trans-Pacific Partnership push waits on cue from Obama’s India visit

EJ Lane SINGAPORE–India is not a member of the 12-nation Trans-Pacific Partnership, but its intellectual property rules governing pharmaceutical patents lie at the core of a dispute ...

The Medicines Co.’s FDA-rejected cardio drug finds EU success

Damian Garde European regulators are recommending approval for The Medicines Company's cangrelor, setting up an overseas nod for a blood-thinning drug rejected by the FDA last year. FierceBiotech ...

Booming biotechs bank $2.7B in follow-on cash

Damian Garde Much of the focus in biotech's recent boom has been on the ease with which companies are making their way onto Wall Street. And, over the past week, a host of drug ...

Novo hopes for European Saxenda launch this year after CHMP nod

Carly Helfand Novo Nordisk's obesity therapy Saxenda is on a roll. Just over a month after snagging FDA approval, the drug scored a positive recommendation on Thursday from Europe's ...

Celgene’s Abraxane wins another OK in Europe

Eric Palmer Celgene's Abaxane is one of those cancer fighters that has proven effective against many forms of cancer, and so the company has sought approvals far and wide, sometimes ...

Osteoarthritis biotech Carbylan swings for a $75M IPO

Damian Garde Palo Alto, CA's Carbylan Therapeutics has set terms for an IPO worth $ 75 million at its midpoint, working to get a treatment for osteoarthritis pain through late-stage ...

Incoming Takeda chief ready to jump on the M&A train with reorg in place

Carly Helfand Step one for incoming Takeda CEO Christophe Weber: Reorganize. Step two? Scout deals, he said Wednesday. FiercePharma News

Scandal-plagued Salix said to consider a sale

Damian Garde Salix Pharmaceuticals, marred by an embarrassing inventory scandal, has hired an investment bank to help it find some strategic alternatives, Reuters reports, including ...

Gilead, AbbVie rack up new payer deals, but hep C obstacles loom across the Atlantic

Tracy Staton The hepatitis C market is breaking new ground all over the place. As payers put the squeeze on Gilead Sciences and AbbVie for discounts in the U.S., England's National ...

J&J and Takeda open up an Israeli biotech incubator

Damian Garde Johnson & Johnson has opened the doors on its Takeda-partnered biotech incubator in Israel, enrolling its first class of startups and advancing its global plan to accelerate ...
Page 1 of 212
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS